Adma Biologics Inc [NASDAQ: ADMA] closed the trading session at $18.67.
The stocks have a year to date performance of 313.05 percent and weekly performance of -3.34 percent. The stock has been moved at 73.19 percent over the last six months. The stock has performed -14.28 percent around the most recent 30 days and changed 3.21 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 4.91M shares, ADMA reached to a volume of 2134599 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Adma Biologics Inc [ADMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $25.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Adma Biologics Inc shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on July 19, 2023. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on October 13, 2022, representing the official price target for Adma Biologics Inc stock. Previously, the target price had yet another raise to $5, while Raymond James analysts kept a Strong Buy rating on ADMA stock.
The Average True Range (ATR) for Adma Biologics Inc is set at 0.96, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 11.53. The Price to Book ratio for the last quarter was 19.03, with the Price to Cash per share for the same quarter was set at 0.37. Price to Free Cash Flow for ADMA in the course of the last twelve months was 55.59 with Quick ratio for the last quarter at 3.26.
ADMA stock trade performance evaluation
Adma Biologics Inc [ADMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.34. With this latest performance, ADMA shares dropped by -14.28% in over the last four-week period, additionally plugging by 73.19% over the last 6 months – not to mention a rise of 399.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 42.94, with the RSI for the last a single of trading hit 37.58, and the three-weeks RSI is set at 46.33 for Adma Biologics Inc [ADMA]. The present Moving Average for the last 50 days of trading for this stock 19.01, while it was recorded at 19.27 for the last single week of trading, and 13.21 for the last 200 days.
Adma Biologics Inc [ADMA]: An insightful look at the core fundamentals
Adma Biologics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.26 and a Current Ratio set at 7.09.
Earnings per share (EPS) analysis for Adma Biologics Inc [ADMA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adma Biologics Inc go to 20.00%.
Adma Biologics Inc [ADMA]: Institutional Ownership
There are presently around $90.94%, or 93.28%% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: BLACKROCK INC. with ownership of 18.64 million shares, which is approximately 8.1462%. VANGUARD GROUP INC, holding 14.52 million shares of the stock with an approximate value of $$162.3 million in ADMA stocks shares; and VANGUARD GROUP INC, currently with $$147.25 million in ADMA stock with ownership which is approximately 5.7546%.
